Phio Pharmaceuticals Completes Second Intraday Wave on INTASYL Compound PH-894 News

DENVER, Colo., Oct 11, 2023 (www.247marketnews.com)- Phio Pharmaceuticals Corp. (NASDAQ:PHIO) has been running since announcing, this morning, the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 11th -15th

After gapping higher to open at $1.57, it hit a $2.25 high, and is trading at $2.20, up $0.81 (+58.27%), on 23,374,120 shares traded. The first wave was basically from the $1.60 level to the $1.90, where it consolidated, followed by its move to the $2.20 level. It’s early enough in the session that it may have another wave or two to go.

Its 52-week range is $0.56 to $4.15. It basically formed a double bottom with its recent 52-week low and the key inflection point is $2.25.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.